GeneScience Reports Mixed Q3 Results as New Drugs Gain Traction
TREE NEWS reports: GeneScience Pharmaceuticals (金赛药业) reported a revenue of 6.676 billion yuan for the first three quarters, down 18.71% year-over-year, while net profit fell 45.26% to 778 million yuan. Despite the overall decline, the company’s new drug portfolio showed strong growth: sales of its gout treatment Jinbeixin surged nearly 300% year-over-year, and Meishiya, after being included in the national reimbursement drug list, saw sales more than double. The company’s recent R&D day highlighted progress in gout, autoimmune diseases, and thyroid disorders, signaling a strategic shift beyond its traditional growth hormone franchise.
Market Implications
The mixed results reflect a classic growth stock in transition: legacy products face pricing pressure and competition, while new therapies are just beginning to contribute. Investors should watch several key areas:
- Diversification progress: Jinbeixin’s rapid uptake demonstrates that GeneScience can replicate its innovation capabilities beyond growth hormone. The drug’s ability to reduce gout flare risk by 90% at 12 weeks addresses a significant unmet need, and its inclusion in reimbursement lists could drive further volume.
- Overseas licensing deals: The agreement with Yarrow for GenSci098, a dual-target antibody for Graves’ disease and thyroid eye disease, brings $70 million upfront and up to $1.365 billion in milestone payments. This validates the company’s R&D and provides non-dilutive funding for further development.
- Pipeline depth: Early-stage assets like GenSci161 (a dual-target antibody for hidradenitis suppurativa) and GenSci120 (for rheumatoid arthritis) show promise, but will require significant investment and time to reach the market.
For the stock, the key question is whether new drugs can offset the decline in growth hormone sales. The company’s ability to execute on clinical trials and secure regulatory approvals will determine its long-term growth trajectory. Near-term volatility is likely as investors digest the earnings decline and await catalysts from pipeline readouts.
Key Takeaways
- GeneScience’s Q3 results show short-term pressure but new drugs are gaining traction.
- Jinbeixin and Meishiya are growing rapidly, validating the company’s diversification strategy.
- The GenSci098 licensing deal provides global validation and upfront cash.
- Investors should monitor pipeline progress and reimbursement decisions for future growth.
